BioTuesdays

Author - Jennifer Poland

Zenabis

Zenabis names Kevin Coft as interim CEO

Zenabis Global (TSX:ZENA) appointed Kevin Coft as interim CEO, effective immediately, replacing Andrew Grieve, whose contract was set to expire shortly. While Mr. Grieve will be returning to his investment business, he...

Stifel cuts CymaBay to hold; PT to $4 from $14

Stifel downgraded CymaBay Therapeutics (NASDAQ:CBAY) to “hold” from “buy” and slashed its price target to $4 from $14 after the company halted development of its sole value driver, seladelpar. The stock closed at $5.55...

Subscribe

Sign up to our weekly BioTuesdays newsletter.